MOMivael Olivera

Mivael Olivera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mivael Olivera has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Integration of immuno-nutritional status into International Federation of Gynecology and Obstetrics risk stratification to predict chemotherapy response and survival in gestational trophoblastic neoplasia

    by Katia Roque, Rossana Ruiz, Marco Galvez-Nino, Melanie Castro-Mollo, Heberth Daniel Vallejos, Iris Otoya, Yomali Ferreyra, Ofelia Coanqui, Mivael Olivera Hurtado de Mendoza, Natalia Valdiviezo, et al.

  • Open Access

    ¿Dónde estamos y hacia dónde vamos en el cáncer de pulmón de células no pequeñas avanzado con mutación EGFR?

    by Jessica Meza-Liviapoma, Katia Roque, Marco Gálvez-Niño, Rossana Ruiz, Ofelia Coanqui, Natalia Valdiviezo, Mivael Olivera, Luis Mas

    El cáncer de pulmón de células no pequeñas (CPCNP) continúa siendo una de las principales causas de mortalidad por cáncer a nivel mundial. La identificación de mutaciones accionables, en especial en el gen del receptor del factor de crecimiento epidérmico (EGFR), ha modificado de manera sustancial el abordaje terapéutico de esta enfermedad. Los Inhibidores de tirosina quinasa (TKI) han demostrado mejoras consistentes en supervivencia libre de progresión y supervivencia global frente a la quimioterapia convencional. No obstante, la resistencia adquirida se desarrolla en la mayoría de los casos, ya sea por mutaciones secundarias, activación de vías alternativas como MET o HER2, o transformación histológica. En los últimos años, el manejo del CPCNP con mutación EGFR ha evolucionado hacia estrategias más complejas que incluyen combinaciones en primera línea, esquemas de intensificación con quimioterapia y el uso de anticuerpos biespecíficos. Asimismo, se han desarrollado terapias dirigidas específicas para mutaciones no frecuentes, como las inserciones del exón 20, y recientemente los anticuerpos fármaco-conjugados han ampliado las alternativas terapéuticas en el escenario pososimertinib. El objetivo de esta revisión es actualizar el estado actual del tratamiento del CPCNP avanzado con mutación EGFR y discutir las estrategias emergentes orientadas a superar los mecanismos de resistencia.

  • Open Access

    Giant Primary Hepatic Endodermal Sinus Tumor: Multidisciplinary Management and Long‐Term Survival

    by Katia Roque, Rossana Ruiz, Renier Cruz, Andrea Ramirez-Aramburú, Eloy Ruiz, Carlos Castaneda, Marco Galvez-Nino, Ofelia Coanqui, Natalia Valdiviezo, Mivael Olivera Hurtado de Mendoza, et al.

    The endodermal sinus tumor (EST), also known as yolk sac tumor, accounts for 20% of germ cell tumor cases, typically occurring in gonadal locations. However, 1%–5% can present with an extragonadal localization. Primary hepatic EST is an extremely rare entity and poses a diagnostic challenge for the appropriate management of this pathology. We present the case of a 34‐year‐old woman who presented with a single hepatic mass associated with elevated alpha‐fetoprotein (AFP) levels. Initially, hepatocellular carcinoma (HCC) was suspected, leading to a right hepatectomy, which resulted in pathology findings consistent with an EST. Following surgery, the patient underwent four courses of BEP chemotherapy, showing a partial response with residual lesions. The patient received two more courses of EP chemotherapy, with a PET CT showing a complete response. At over 5 years of follow‐up, the patient remains clinically stable, with negative tumor markers, no evidence of disease, and leading a normal life. Primary hepatic EST is an infrequent but important differential diagnosis of HCC, particularly in young women without cirrhosis who present with markedly elevated AFP levels. Early biopsy confirmation and multidisciplinary management are essential, as this chemosensitive tumor may achieve long‐term survival with timely systemic treatment.

  • Open Access

    Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study

    by D. Lorusso, N. Colombo, C. Dubot, M.V. Cáceres, K. Hasegawa, R. Shapira-Frommer, P. Salman, E. Yañez, M. Gümüş, M. Olivera, et al.


  • Top Cited Papers

    First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

    by Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari, Coraline Dubot, M. Valeria Caceres, Kosei Hasegawa, Ronnie Shapira-Frommer, Pamela Salman, Eduardo Yañez, Mahmut Gümüş, et al.

    Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The phase III, double-blind KEYNOTE-826 trial of pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles plus platinum-based chemotherapy, with or without bevacizumab, showed statistically significant survival benefits with the addition of pembrolizumab for patients with persistent, recurrent, or metastatic cervical cancer (primary data cutoff: May 3, 2021). This article reports the protocol-specified final overall survival (OS) results tested in the PD-L1 combined positive score (CPS) ≥1, all-comer, and CPS ≥10 populations. At the final data cutoff (October 3, 2022), the median study follow-up duration was 39.1 months (range, 32.1-46.5 months). In the PD-L1 CPS ≥1 (N = 548), all-comer (N = 617), and CPS ≥10 (N = 317) populations, median OS with pembrolizumab–chemotherapy versus placebo–chemotherapy was 28.6 months versus 16.5 months (hazard ratio [HR] for death, 0.60 [95% CI, 0.49 to 0.74]), 26.4 months versus 16.8 months (HR, 0.63 [95% CI, 0.52 to 0.77]), and 29.6 months versus 17.4 months (HR, 0.58 [95% CI, 0.44 to 0.78]), respectively. The incidence of grade ≥3 adverse events was 82.4% with pembrolizumab–chemotherapy and 75.4% with placebo–chemotherapy. These results show that pembrolizumab plus chemotherapy, with or without bevacizumab, continued to provide clinically meaningful improvements in OS for patients with persistent, recurrent, or metastatic cervical cancer.


  • Open Access

    Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru

    by Marco Galvez‐Nino, Rossana Ruiz, Katia Roque, Ofelia Coanqui, Natalia Valdivieso, Mivael Olivera, Apar Kishor Ganti, Luis Mas

    Background: Despite the advances in the management of advanced non–small cell lung cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in Latin America, even in countries with a higher rate of targetable mutations. The aim of this study is to evaluate the clinical outcomes of anti‐epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) treatment in a Peruvian real‐world setting.Methods: This is a retrospective study of recurrent or advanced NSCLC EGFR mutated patients diagnosed and treated with anti‐EGFR TKI at Instituto Nacional de Enfermedades Neoplásicas (INEN) between January 1, 2015 to December 31, 2020. The outcomes were objective response rate (ORR), progression free survival (PFS), and overall survival (OS).Results: We identify 613 stage IV or recurrent NSCLC patients who were tested for EGFR mutations and found a pathogenic mutation in 39.5% of patients. Only 51.2% of them received anti‐EGFR TKI as institutional treatment. ORR was 58%, after median follow‐up of 32 months, the estimated median PFS was 13.9 months (11.1–16.7 months), and the estimated median OS was 21.7 months (18.5–24.9 months). No differences were found in PFS according to line of treatment or brain metastases at diagnosis (p = 0.46 and p = 0.07, respectively), respect to OS there were no differences line of treatment (p = 0.12), significant difference were found in presence of brain metastases (p = 0.006).Conclusion: Our study demonstrates that erlotinib for advanced NSCLC harboring EGFR‐activating mutations is effective even in patients usually excluded from clinical trial, like those previously exposed to one or more lines of chemotherapy or with brain metastases.


  • Genomic profile by liquid biopsy of Peruvian patients with lung cancer.

    by Marco Galvez-Nino, Katia Roque Perez, Melanie Wendy Castro, Rossana Ruiz, Natalia Valdivieso, Ofelia Coanqui, Mivael Olivera Hurtado de Mendoza, Edgar Amorin, Luis Mas

    E15027 Background: The optimal treatment of advanced NSCLC patients is currently led by genomic profiling with the goal of detecting actionable mutations with an approved targeted therapy. However, tissue DNA samples are not always available to perform this assays. In this context, liquid biopsy has emerged as a valuable tool for providing the best treatment option. Methods: Retrospective study held at Instituto Nacional de Enfermedades Neoplasicas (INEN), Lima - Peru, between January 2019 and September 2021 to assess the genomic profile of 190 newly diagnosed advanced NSCLC patients through liquid biopsy. Blood samples were profiled with the FoundationOne Liquid Biopsy assay. We describe frequency of pathogenic and targetable genetic alterations, as well as the survival outcomes. Genomic and clinical data were recorded from clinical files. Results: The median age was 63 years (26-90), 66.3% were women, 15.3% smokers, 26.3% had exposure to biomass, 22.6% had a first-degree family history of cancer. The most frequent histological type was adenocarcinoma (86.8%). Regarding genomic profile, 183 patients (96.3%) had at least one pathogenic genetic alteration, the most frequent altered genes were TP53 (54.7%), EGFR (50.5%), DNMT3A (17.9%), KRAS (9.5%) and NF1 (6.8%). 116 patients (61%) had a targetable mutation: EGFR Ex19del/ins (27.4%), EGFR L858R/L861Q (17.9%), ALK rearrangements (5.8%), BRAF V600E (3.2%), RET fusions (1.6%), METex14 skipping (1.6%), KRAS G12C (1.6%), ROS 1 (1.1%), and NTRK (0.5%). Of these, 71 patients (65.5%) were able to access target therapy. For the latter, estimated median PFS and OS were 14.0 months (9.3 – 18.6) and 17.8 months (8.2 – 27.4), respectively. Conclusions: Peruvian NSCLC patients represent a population with a high frequency of pathogenic and targetable mutations, being EGFR mutations and ALK rearrangements the most prevalent ones. Despite limited access, a great proportion of patients received target therapy, achieving remarkable survival.

  • Open Access

    Epidemiology of thymic epithelial tumors: 22‐years experience from a single‐institution

    by Patricia Rioja, Rossana Ruiz, Marco Galvez‐Nino, Sophia Lozano, Natalia Valdiviezo, Mivael Olivera, Octavio Cabero, Maria Eugenia Guillen, Alberto De La Guerra, Edgar Amorin, et al.

    Background: To assess the correlation of WHO histological classification and Masaoka–Koga staging system of thymic epithelial tumors (TETs) with prognosis.Methods: We retrospectively analyzed 83 patients with TETs in the Instituto Nacional de Enfermedades Neoplasicas between 1996 to 2018. We analyzed the clinical stages, histological types and treatment modalities and attempted to determine the impact on overall survival. The data was retrieved from clinical files and reviewed by a pathologist who reclassificated according to the 2004 WHO classification system. The staging was performed with the Masaoka–Koga staging system. Survival curves were constructed with Kaplan‐Meir method.Results: There was a total of 83 patients with a median age of 55 years old included in the study. The histological type corresponded to thymoma (T) in 63.8% (n = 53) and to thymic carcinoma (TC) in 36.1%. T were type A, AB, B1, B2 and B3 in 14.4%, 18%, 12%, 3.6%, 7.4% of cases, respectively. The proportion of advanced disease (Masaoka stage III–IV) was high (65%). With a median follow‐up of 88.4 months, median overall survival (OS) was 81.6 months for T and 12.3 months for TC (P = 0.01). Univariate analysis showed that sex, histological type, clinical stage and surgery (P = 0.01) were significant independent prognostic factors. On multivariate analysis, histology type and Masaoka–Koga staging had an effect on survival.Conclusions: The results indicates a clear association between the WHO histological classification and Masaoka–Koga staging system with survival. We found a higher proportion of TETs with advanced disease at diagnosis. Further research are required and collaboration is important to foster knowledge focused on classification and treatment.Key points: Significant findings of the study: The WHO histological classification, the Masaoka–Koga system and surgery treatment were associated with overall survival.What this study adds: To determine prognosis factors in TETs.


  • P2.16-25 Epidemiology of Advanced Lung Cancer in Peru

    by R. Ruiz, M. Galvez Nino, K. Roque Perez, J. Moreno, N. Valdivieso, M. Olivera, J. Rivera, E. Amorin, L. Raez, L. Mas


  • Open Access

    Citorreducción óptima en cáncer de ovario avanzado tratado con paclitaxel a dosis densa y carboplatino seguido de cirugía de intervalo en el Instituto Nacional de Enfermedades Neoplásicas del Perú

    by Cindy Alcarraz, Johana Muñiz, Luis Mas, Mivael Olivera, Zaida Morante, Manuel Alvarez, Raul Mantilla, Jhajaira Araujo, Joseph Pinto

    Citorreducción óptima en cáncer de ovario avanzado tratado con paclitaxel a dosis densa y carboplatino seguido de cirugía de intervalo en el Instituto Nacional de Enfermedades Neoplásicas del Perú